Melb firm trials muscular dystrophy drug, page-14

Re split global sales...

Yes, spot on...and a good strategy to accelerate sales and lower risk.

That is what Sarepta is doing with Roche - they are keeping US market and giving license to Roche outside US.

Statistics will tell us that it's a long haul for minnows like ANP to take a drug all the way to market.

Having a great product is only the start, the global footprint and sales operations engine is probably just as important for commercialisation.

I just can't see it happening for following reasons:

- Given Sarepta's desire to own the space.

- Willingness of giants like Roche to play in that space (and Pfizer etc)

- Phase 2 valuation is reasonable....for cashed up giants like Sarepta / Roche / Pfizer....and appealing for top 40 to say yes.

- Top 40 own over 50% of ANP stock - bird in the hand is worth two in the bush.